

3. van der Meide WF, Schoone GJ, Faber WR, Zeegelaar JE, de Vries HJ, Ozbel Y, et al. Quantitative nucleic acid sequence-based assay as a new molecular tool for the detection and quantification of *Leishmania* parasites in skin biopsies. *J Clin Microbiol*. 2005;43:5560–6.
4. Silveira FT, Lainson R, Corbett CE. Further observations on clinical, histopathological, and immunological features of borderline disseminated cutaneous leishmaniasis caused by *Leishmania (Leishmania) amazonensis*. *Mem Inst Oswaldo Cruz*. 2005;100:525–34.
5. Rotureau B, Ravel C, Nacher M, Couppié P, Curtet I, Dedet JP, et al. Molecular epidemiology of *Leishmania (Viannia) guyanensis* in French Guiana. *J Clin Microbiol*. 2006;44:468–73.
6. Burgos A, Hudson J. Annotated list of the phlebotominae (diptera) of Suriname. *Mem Inst Oswaldo Cruz*. 1994;89:171–8.
7. Silveira FT, Lainson R, Shaw JJ, De Souza AA, Ishikawa EA, Braga RR. Cutaneous leishmaniasis due to *Leishmania (Leishmania) amazonensis* in Amazonian Brazil, and the significance of a negative Montenegro skin-test in human infections. *Trans R Soc Trop Med Hyg*. 1991;85:735–8.
8. Rotureau B, Joubert M, Clyti E, Djossou F, Carne B. Leishmaniasis among gold miners, French Guiana. *Emerg Infect Dis*. 2006;12:1169–70.

Address for correspondence: Wendy van der Meide, Koninklijk Instituut voor de Tropen/Royal Tropical Institute, KIT Biomedical Research, Meibergdreef 39, 1105 AZ, Amsterdam, the Netherlands; email: wfmeide@yahoo.com

Household Transmission of Carbapenemase- producing *Klebsiella* *pneumoniae*

To the Editor: Since its first description in 2001, carbapenemase-producing *Klebsiella pneumoniae* has become a frequent nosocomial pathogen in the eastern United States (1).

This bacterium was introduced into Israel in 2005 and is endemic now in several hospitals in the country (2). We recently documented transmission of this organism within a household, the source being a debilitated patient who returned home after a long hospitalization.

A 73-year-old man had a urologic procedure (transurethral resection of the bladder neck) in a community hospital in early October 2007. He was initially evaluated on September 23, 2007, at an outpatient clinic where a routine urine sample was obtained for culture. Carbapenemase-producing *K. pneumoniae* was cultured. Identification and susceptibility testing of the isolate were completed by using the VITEK 2 system (bioMérieux, Marcy l'Etoile, France). *K. pneumoniae* carbapenemase was confirmed by using the modified Hodge test (3). Two repeat urine cultures grew the same organism; however, a stool culture was negative for carbapenemase-producing *K. pneumoniae*.

The medical history of the patient included hypertension and carcinoma of the prostate gland that was treated with high-intensity focused ultrasound in May 2007, followed by transurethral resection of prostate in June 2007. The 2 procedures were performed in 2 different private hospitals, and each required a 24-hour hospitalization. No carbapenemase-producing *K. pneumoniae* was documented in these hospitals. Two months before detection of carbapenemase-producing *K. pneumoniae*, the patient received a 1-week course of oral amoxicillin-clavulanate for presumed urinary tract infection, although urine culture obtained on July 29, 2007 was sterile. A repeat urine culture 2 weeks later (August 13, 2007) remained sterile.

Because the circumstances of strain acquisition and patient characteristics were not typical for epidemiology of carbapenemase-producing *K. pneumoniae* (3), he was further questioned about possible contacts of

relevance. The patient disclosed that his wife, who had amyotrophic lateral sclerosis that required mechanical ventilation, had been hospitalized in a tertiary hospital in the Tel Aviv area for 9 weeks until July 19, 2007. After discharge, she has been staying at home where she was cared for by her son, sister, and nurses; the patient stated that he had limited contact with his wife (he did not participate in her care). The infection control unit of the tertiary hospital was contacted, and the name of the wife was identified in the hospital registry. Carbapenemase-producing *K. pneumoniae* was isolated from her urine on June 8, 2007.

Despite limited contact, the patient probably acquired carbapenemase-producing *K. pneumoniae* from his wife, who was a documented carrier of this organism. Because his early urine cultures (taken after his wife was discharged from hospital) were sterile, we can assume that the transmission of the organism occurred at their home. We cannot rule out that the strain was transferred by an intermediary, such as the couple's son. It is unlikely that the organism was acquired at the private hospitals from which no case of carbapenemase-producing *K. pneumoniae* was reported (in Israel reporting carbapenemase-producing *K. pneumoniae* isolates to health authorities is mandatory). Also, the patient had 2 negative urine cultures.

Carbapenemase-producing *K. pneumoniae* is a recent addition to the pool of multidrug-resistant nosocomial pathogens. Most publications on this organism have focused on issues of structural and molecular epidemiology. Little is known regarding clinical characteristics and importance of infection with this organism. Until now, the strain has been recovered only from hospitalized patients with a longer hospital stay, those given multiple antimicrobial drug courses, and those mechanically ventilated (3,4). The strain can colonize the urinary,

intestinal, and respiratory tracts, as well as wounds; bloodstream infection is associated with higher death rates than infection at other sites (4). Hand carriage is probably the biggest factor in transmission of extended-spectrum β -lactamase producers, and there is little evidence to suggest that carriers of carbapenemase-producing *K. pneumoniae* would be different. Environmental contamination plays a limited role in transmission of the organism (3). Caregivers should be aware that multidrug-resistant organisms of nosocomial origin can be transmitted in the community (5). Acquisition of such strains is probably of negligible importance in an otherwise healthy person. However, consequences may be different if the recipient of the strain is a debilitated patient.

**Tamar Gottesman,*
Orly Agmon,* Orna Shwartz,*
and Michael Dan***

*Edith Wolfson Hospital, Holon, Israel

References

- Desphande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing *Enterobacteriaceae*: report from the SENTRY Antimicrobial Surveillance Program (2000–2004). *Microb Drug Resist*. 2006;12:223–30.
- Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant *Klebsiella pneumoniae* strains in an Israeli hospital. *Antimicrob Agents Chemother*. 2007;51:3026–9.
- Patel JB, Srinivasan A. Carbapenem resistance in *Enterobacteriaceae*. Presented at the 107th American Society for Microbiology General Meeting; 2007 May 21–25; Toronto, Ontario, Canada.
- Agmon O, Shwartz O, Gottesman T, Dan M. A year with KPC at an urban hospital in Israel. Presented at the 8th Congress of the International Federation of Infection Control; 2007 Oct 18–21; Budapest, Hungary.
- Calbo E, Romani V, Xercavins M, Gómez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to *Escherichia coli* harbouring extended-spectrum beta-lactamases. *J Antimicrob Chemother*. 2006;57:780–3.

Address for correspondence: Michael Dan, Infectious Diseases Unit, Edith Wolfson Hospital, Holon 58100, Israel; email: midan@post.tau.ac.il

Alternatives to Ciprofloxacin Use for Enteric Fever, United Kingdom

To the Editor: In cases of typhoid and paratyphoid fever, it is often necessary to commence treatment before the results of laboratory sensitivity tests are available. It is therefore important to be aware of optional drug therapies available because some organisms may be resistant to key antimicrobial drugs. For typhoid and paratyphoid, ciprofloxacin has become the first-line drug of choice since the widespread emergence and spread of strains resistant to chloramphenicol, ampicillin, and trimethoprim (1).

The Laboratory of Enteric Pathogens (LEP) of the Health Protection Agency of England and Wales is the reference center for *Salmonella enterica* serovars Typhi and Paratyphi A for the United Kingdom; as such, this laboratory receives isolates from all cases of infection. Isolates are screened by breakpoint for resistance to antimicrobial drugs at the following levels: chloramphenicol, 8 mg/L; ampicillin, 8 mg/L; trimethoprim, 2 mg/L; ciprofloxacin, 0.125 mg/L (decreased susceptibility); and 1.0 mg/L (high-level resistance), ceftriaxone, 1 mg/L, and cefotaxime, 1 mg/L. The levels for testing for resistance to chloramphenicol, ampicillin, trimethoprim, ceftriaxone, and cefotaxime correspond to internationally accepted therapeutic levels for these antimicrobial agents. In contrast, the levels for ciprofloxacin (0.125 and 1.0 mg/L) have been

chosen after observations of treatment failures at levels when used at below the expected recommended serum concentrations (2,3). Since 2005, a proportion of isolates exhibiting decreased susceptibility and high-level resistance to ciprofloxacin have been tested for resistance to azithromycin by Etest (AB Biodisk, Solna, Sweden), using drug-sensitive strains of *S. Typhi* and *S. Paratyphi A* as controls.

From January 2001 through December 2006, LEP reported 1,215 cases of *S. Typhi* infection and 1,274 cases of *S. Paratyphi A* infection. Of these, $\approx 60\%$ (1,493) reported recent travel abroad; India and Pakistan were the most frequently visited countries (4). Other cases were associated with persons who had a history of such travel, but the numbers involved were difficult to document accurately because of underreporting of foreign travel and other communication problems.

For *S. Typhi*, the occurrence of isolates resistant to ciprofloxacin at 0.125 mg/L increased from 60 (35%) of 170 in 2001 to 169 (70%) of 240 cases in 2006, with 4.8 (2%) of isolates in 2006 resistant at 1.0 mg/L (Table). The corresponding figures for *S. Paratyphi A* were 58 (25%) of 232 cases in 2001, rising to 84% in 2004, with an incidence of 73% in 2006; 9% of these were resistant to ciprofloxacin at 1.0 mg/L (Table). Moreover, in 2006, 56 isolates of *S. Typhi* (23% of total) exhibited resistance to chloramphenicol, ampicillin, and trimethoprim, 54 (96%) were also resistant to ciprofloxacin at 0.125 mg/L. When tested for resistance to ceftriaxone and cefotaxime, none of the isolates (either *S. Typhi* or *S. Paratyphi A*) were resistant at 1.0 mg/L.

Although the levels of resistance to ciprofloxacin were for the most part below that regarded as therapeutic (MIC 0.25–1.0 mg/L), at least 21 treatment failures have been documented since 2005. These findings demonstrate that the efficacy of ciprofloxacin for first-line treatment of